[新聞] Amazon Will Start Selling Cheap Hair-Loss Drugs.

看板Stock (股票)作者NoAfraid (小子難纏不得安寧)時間3小時前 (2024/11/16 04:43)推噓5(5推 0噓 2→)

留言7則, 5人參與討論串1/1

原文標題： Amazon Will Start Selling Cheap Hair-Loss Drugs. It's a Huge Threat for This Stock. 原文連結： https://tinyurl.com/2sezmx42 發布時間： Updated Nov 14, 2024, 2:11 pm EST / Original Nov 14, 2024, 11:08 am EST 記者署名： Josh Nathan-Kazis 原文內容： Amazon.com’s latest lurch into the healthcare industry, announced Thursday morning, poses an extraordinary threat to the many telehealth companies selling cheap generics to treat hair loss and erectile dysfunction. Amazon’s prices appear lower than those being offered by companies such as Hims & Hers Health and Ro, and are available to all members of its Prime subscription service. Amazon’s prices appear set to undercut the long list of competing telehealth companies that rely on aggressive marketing campaigns to sell low-cost generics online. Shares of Hims & Hers were down 22% after the announcement. Amazon has made plenty of forays into the healthcare business, with mixed success. This time, however, its new competitors are far less formidable than the managed care companies and retail pharmacy chains Amazon has sought to challenge in the past. Amazon will charge $16 a month for the generic hair-loss pill finasteride. Hims advertises a $22-a-month price for the same medicine, while Ro, a privately held competitor, charges $20 per month. “Access to affordable health and wellness solutions is important for every individual and we’re committed to offering access to high-quality personalized solutions across the Hims & Hers platform,” Hims said Thursday morning. Ro didn’t respond to a request for comment. Amazon is charging $19 a month for erectile dysfunction pills and $10 per month for an antiaging skin cream. A telehealth visit with primary care provider Amazon One Medical to get the prescriptions costs as little as $29. “We don’t know how successful it will be, but also note that this is a serious competitive threat being introduced to the market,” Leerink Partners analyst Michael Cherny wrote in a Thursday morning note. The number of telehealth companies competing to sell cheap generics online has grown this year amid a weight-loss drug gold rush. Companies like Hims realized they could sell copycat versions of Novo Nordisk’s GLP-1 medicine Wegovy made legally by compounding pharmacies. The industry is now full of large and small players, none of them dominant, and few prepared to withstand competition from Amazon. Amazon is not offering compounded GLP-1 drugs. The compounded GLP-1 drug market is controversial and could dry up quickly if the Food and Drug Administration determines that Novo’s drug is no longer in shortage. Amazon’s new offering is based around Amazon One Medical, the primary care chain it bought for $3.9 billion in 2023. The company launched a pay-per-visit telehealth offering through One Medical earlier this year. Patients prescribed a generic treatment through the new program launched Thursday will buy the medicine through Amazon Pharmacy, a delivery prescription service Amazon opened in 2020. Amazon has long eyed the healthcare sector, and has sparked periodic selloffs in healthcare stocks on fears that Amazon’s scale would allow it to dominate parts of the industry. In 2018, pharmacy stocks plunged when Amazon announced a deal to buy the online pharmacy PillPack. There were also worries over an Amazon program called Haven Healthcare, which Amazon ran in partnership with Berkshire Hathaway and JPMorgan Chase and briefly appeared to threaten the managed care sector. In 2022, fears that Amazon would buy the home health-services firm Signify Health put pressure on shares of large managed care companies. (CVS Health eventually bought Signify for $8 billion.) In taking on telehealth providers, Amazon appears to have chosen a much less formidable target. They may not survive the onslaught. 心得/評論：亞馬遜要進軍禿頭藥物治療市場 Bezos: 我退休了就開始臭我了? 除此之外也要進軍勃X功能障礙藥物市場每月收費 19 美元各位應該是負擔的起 (我是花不到這個錢) 儘管亞馬遜涉足醫療保健業務的成效參差不齊但這次依然會給其他競爭對手造成不小威脅首先是價格硬是比其他對手便宜其次是亞馬遜的規模與通路確實有可能在當今這個沒有一家佔據主導地位的行業主導該行業的部分領域。更重要的這次的競爭對手遠沒有過去試圖挑戰的管理醫療公司和零售藥房連鎖店那麼強大也因此雖然不知道會取得多大成功但威脅已造成消息公佈後，Hims & Hers 的股價下跌了 22% -- ※ 發信站: 批踢踢實業坊(ptt.cc), 來自: 123.193.250.85 (臺灣) ※ 文章網址: https://www.ptt.cc/bbs/Stock/M.1731703411.A.BC8.html ※ 編輯: NoAfraid (123.193.250.85 臺灣), 11/16/2024 04:44:52